Method for growing stem cells in suspension in a bioreactor

Abstract

The present invention relates to a method for expanding pluripotent stem cells (PSCs) in suspension culture in a bioreactor, the method comprising: (i) adding an inhibitor of ROCK (ROCKi) to pluripotent stem cells cultured in suspension in a bioreactor; (ii) adding a cell dissociation agent, thereby dissociating pluripotent stem cell aggregates; (iii) diluting the cell dissociation agent added in step (ii) by adding an excess volume of culture medium sufficient to reduce the concentration of the cell dissociation agent to a concentration at which cell aggregates can reform; and (iv) culturing the mixture obtained in step (iii) under appropriate conditions that allow the proliferation of PSCs. TIFF2023505421000004.tif59147

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority from European Patent Application Publication No. 19 215091.0, filed December 11, 2019, the contents of which are incorporated herein by reference in their entirety for all purposes.

[0002] Technical field of the invention The present invention relates to a method for expanding pluripotent stem cells (PSCs) in suspension culture in a bioreactor. [Background technology]

[0003] background Pluripotent stem cells (PSCs) are adherent cells and are therefore typically cultured in cell culture vessels such as flasks, where they adhere to the bottom of the vessel. To promote adhesion, the bottom of the vessel is typically coated with extracellular matrix (ECM) proteins. However, this cell culture method is not useful for producing the large numbers of PSCs required for clinical applications. Cultivation in cell culture flasks is time-consuming, labor-intensive, and requires a significant amount of materials (culture medium and plasticware). Suspension culture in stirred-tank bioreactors has been described as an alternative to adherent culture. In this case, PSCs form adherent aggregates rather than growing as a single cell layer on the bottom of the cell culture vessel. Therefore, supplementation of ECM proteins during suspension culture to enable the formation of cell aggregates is not necessary. Suspension culture is considered more efficient because it allows for controlled culture conditions even at high cell numbers and requires fewer materials and time.

[0004] However, continuous growth of PSCs in suspension culture results in a continuous increase in the size of the aggregates. Once the aggregate diameter exceeds a certain size, the cells within the aggregates are no longer adequately supplied with nutrients and / or growth factors or other signaling molecules, causing them to spontaneously differentiate or become apoptotic. Therefore, to continuously grow PSCs, the aggregates must be dissociated, and the resulting single cells must be reseeded ("passaged"). However, passaging in suspension culture poses several problems: because PSCs are sensitive to external influences, dissociation of the aggregates can lead to a decrease in PSC viability or spontaneous differentiation. Furthermore, because the cell culture medium must be rapidly removed from the aggregates, automating this step in a closed system when a large number of cells are present is challenging.

[0005] The most commonly used method for aggregate dissociation is enzymatic digestion. In this method, PSC adhesion molecules are proteolytically cleaved, thereby separating the cells from one another. The use of enzymes or enzyme-containing solutions, including Accutase, Accumax, trypsin, TrypLE Select, and collagenase B, has been described. The enzymatic reaction must be stopped to prevent overdigestion, which could potentially lead to lysis or apoptosis again. Stopping the enzymatic reagent is usually achieved by extensive dilution or by adding a stop reagent followed by removal by centrifugation. Furthermore, enzymatic digestion affects PSC proliferation and aggregate formation because membrane-bound adhesion molecules are removed and must be reformed during the process. Furthermore, in many cases, PSCs are completely detached from one another, which can adversely affect their pluripotency and viability.

[0006] Mechanical dissociation of cell aggregates has also been described in the art.In this case, aggregates are forcibly passed through a sieve with a pore size that allows them to be subdivided into smaller aggregates.Often, aggregates are pretreated with dissociation reagent.This method also gives PSCs environmental stress, and therefore PSCs may become apoptotic or start to differentiate.

[0007] Enzymatic and mechanical dissociation are usually performed manually to allow for control and monitoring of the entire process. Furthermore, aggregates or cells are typically separated from the cell culture medium or dissociation reagent by centrifugation, which can lead to cell "clumping." Both methods are particularly avoided in GMP manufacturing processes for therapeutic products. This is not only because they are labor-intensive and therefore expensive, but also because each manual unit operation increases the risk of microbial contamination and lot-to-lot variability.

[0008] Thus, there remains a need for a cell dissociation or passaging method that allows for the propagation of PSCs in a closed system, where the entire process of dissociating and reforming PSC aggregates can be repeatedly performed without removing either the cells or the aggregates from the system and without subjecting the cells to the stresses associated with enzymatic / mechanical digestion and / or centrifugation. Summary of the Invention

[0009] The technical problem is solved by the subject matter defined in the claims. A method for expanding pluripotent stem cells (PSCs) in suspension culture in a bioreactor is presented herein.

[0010] Accordingly, the present invention relates to a method for expanding pluripotent stem cells (PSCs) in suspension culture in a bioreactor, the method comprising the steps of: (i) adding an inhibitor of ROCK (ROCKi) to pluripotent stem cells cultured in suspension in a bioreactor; (ii) adding a cell dissociation agent, thereby dissociating the pluripotent stem cell aggregates; (iii) diluting the cell dissociation agent added in step (ii) by adding an excess volume of culture medium sufficient to reduce the concentration of the cell dissociation agent to a concentration at which cell aggregates can reform; and (iv) culturing the mixture obtained in step (iii) under suitable conditions that allow proliferation of PSCs.

[0011] The cell dissociation reagent is preferably a chelating agent, and preferably the chelating agent is selected from the group consisting of ethylenediaminetetraacetate (EDTA), ethyleneglycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), iminodisuccinic acid (IDS), polyaspartic acid, ethylenediamine-N,N'-disuccinic acid (EDDS), citrate, citric acid, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), and methylglycine diacetic acid (MGDA).

[0012] Preferably, the cell dissociation reagent is selected from the group consisting of EDTA, citrate, citric acid, or a combination thereof.

[0013] Preferably, the final concentration of the cell dissociation agent, such as EDTA, citric acid, or citrate in step (ii) is at least 100 μM, in the range of about 100 to about 1000 μM, in the range of about 250 to about 750 μM, in the range of about 400 to about 600 μM, or about 500 μM, preferably about 500 μM, of EDTA, citric acid, or citrate.

[0014] Preferably, the concentration of the cell dissociation agent, such as EDTA, citric acid, or citrate in step (iii), after adding the excess volume of culture medium, is about 100 μM or less, about 95 μM or less, about 90 μM or less, about 80 μM or less, about 70 μM or less, in the range of about 100 to about 1 μM EDTA, citric acid, or citrate, or in the range of about 90 to about 1 μM EDTA, citric acid, or citrate.

[0015] Preferably, the excess volume is at least 5 times greater than the volume of cell dissociation agent. Preferably, by adding at least a 5-fold excess volume, cell dissociation is stopped and aggregate reformation is initiated.

[0016] Preferably, the culture medium in (iii) contains ROCKi.

[0017] Preferably, the method further comprises the step of (v) replacing the medium with medium essentially free of ROCKi.

[0018] Preferably, step (iv) is carried out for about 1 to about 3 days, preferably about 2 days.

[0019] Preferably, step (v) begins about 1 to about 3 days, preferably about 2 days, after step (iii).

[0020] Preferably, the ROCKi is selected from the group consisting of AS1892802, fasudil hydrochloride, GSK 269962, GSK 429286, H 1152, HA 1100, OXA 06, RKI 1447, SB 772077B, SR 3677, TC-S 7001, thiazovivin, Y27632, and combinations thereof. Preferably, the ROCKi is Y27632. Preferably, Y27632 is added to a final concentration of about 10 μM.

[0021] Preferably, ROCKi is added in step (i) about 2 to about 4 hours before step (ii).

[0022] Preferably, the addition of an excess volume of culture medium in step (iii) reduces the number of cells in the culture medium to about 1 x 10 5 ~Approx. 1×10 6 cells / ml, about 1.5 to about 7.5×10 5 cells / ml, approximately 2×10 5 ~Approx. 5×10 5 cells / ml, approximately 2×10 5 ~Approx. 3×10 5 cells / ml, or approximately 2.5 x 10 5 cells / ml. Preferably, the culture medium is selected from the group consisting of IPS-Brew, E8, StemFlex, mTeSR1, and PluriSTEM. Preferably, the culture medium is iPSC-Brew.

[0023] Preferably, the culture media in steps (i) and (iii) are essentially the same.

[0024] Preferably, the temperature of the culture medium is about 30 to 50°C, about 35 to 40°C, about 36 to 38°C, or about 37°C, preferably 37°C.

[0025] Preferably, steps (i)-(iv) or (i)-(v) are repeated 1, 2, 3, 4, 5, at least 5, or at least 10 times.

[0026] Preferably, the PSCs maintain pluripotency after each repetition of steps (i) to (iv) or (i) to (v).

[0027] Preferably, the pluripotent stem cells are selected from the group consisting of induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), parthenogenetic stem cells (pPSCs), and nuclear transfer-derived PSCs (ntPSCs). Most preferably, the pluripotent stem cells are iPSCs. In another more preferred embodiment, the pluripotent stem cells are ESCs. In another more preferred embodiment, the pluripotent stem cells are parthenogenetic stem cells.

[0028] Preferably, the pluripotent stem cells are TC1133 cells.

[0029] Preferably, the aggregates of step (ii) have an average diameter of from about 180 μm to about 250 μm, preferably from about 200 μm to about 250 μm, most preferably about 200 μm.

[0030] Preferably, the aggregates are dissociated in step (ii) for at least about 1 minute, at least about 2 minutes, at least about 3 minutes, at least about 5 minutes, at least about 10 minutes, 1 to 20 minutes, about 10 to about 20 minutes, about 10 to about 15 minutes, or up to about 15 minutes, preferably about 15 minutes. [The present invention 1001] 1. A method for expanding pluripotent stem cells (PSCs) in suspension culture in a bioreactor, the method comprising the steps of: (i) adding an inhibitor of ROCK (ROCKi) to pluripotent stem cells cultured in suspension in a bioreactor; (ii) adding a cell dissociation agent, thereby dissociating the pluripotent stem cell aggregates; (iii) diluting the cell dissociation agent added in step (ii) by adding an excess volume of culture medium sufficient to reduce the concentration of the cell dissociation agent to a concentration at which cell aggregates can reform; and (iv) culturing the mixture obtained in step (iii) under suitable conditions that allow proliferation of PSCs. [The present invention 1002] 1001. The method of claim 1001, wherein the cell dissociation reagent is a chelating agent, and preferably, the chelating agent is selected from the group consisting of ethylenediaminetetraacetate (EDTA), ethyleneglycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), iminodisuccinic acid (IDS), polyaspartic acid, ethylenediamine-N,N'-disuccinic acid (EDDS), citrate, citric acid, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), methylglycine diacetic acid (MGDA), and combinations thereof. [The present invention 1003] The method of claim 1002, wherein the cell dissociation reagent is EDTA. [The present invention 1004] 1003. The method of claim 1003, wherein the final concentration of EDTA in step (ii) is at least 100 μM EDTA, in the range of about 100 to about 1000 μM EDTA, in the range of about 250 to about 750 μM EDTA, in the range of about 400 to about 600 μM EDTA, or about 500 μM EDTA, preferably about 500 μM EDTA. [The present invention 1005] 10. The method of claim 1003 or 1004, wherein the concentration of EDTA in step (iii) after adding the excess volume of culture medium is about 100 μM or less, about 95 μM or less, about 90 μM or less, about 80 μM or less, about 70 μM or less, in the range of about 100 to about 1 μM EDTA, or in the range of about 90 to about 1 μM EDTA. [The present invention 1006] Any of the aforementioned methods of the present invention, wherein the excess volume is at least 5 times greater than the volume of the cell dissociation agent. [The present invention 1007] Any of the methods of the present invention, wherein the culture medium of (iii) comprises ROCKi. [The present invention 1008] Any of the aforementioned methods of the present invention further comprising the steps of: (v) replacing the medium with medium essentially free of ROCKi. [The present invention 1009] Any of the methods of the present invention described above, wherein step (iv) is carried out for about 1 to about 3 days, preferably about 2 days. [The present invention 1010] 1008. The method of claim 10, wherein step (v) begins about 1 to about 3 days, preferably about 2 days, after step (iii). [The present invention 1011] Any of the methods of the preceding invention, wherein the ROCKi is selected from the group consisting of AS1892802, fasudil hydrochloride, GSK 269962, GSK 429286, H 1152, HA 1100, OXA 06, RKI 1447, SB 772077B, SR 3677, TC-S 7001, thiazovivin, Y27632, and combinations thereof. [The present invention 1012] Any of the aforementioned methods of the present invention, wherein ROCKi is Y27632. [The present invention 1013] 1012. The method of claim 1012, wherein Y27632 is added to a final concentration of about 10 μM. [The present invention 1014] Any of the methods of the present invention, wherein ROCKi is added in step (i) about 2 to about 4 hours before step (ii). [The present invention 1015] The addition of an excess volume of culture medium in step (iii) reduces the number of cells in the culture medium to about 1 x 10 5 ~Approx. 1×10 6 cells / ml, about 1.5 to about 7.5×10 5 cells / ml, approximately 2×10 5 ~Approx. 5×10 5 cells / ml, approximately 2×10 5 ~Approx. 3×10 5 cells / ml, or approximately 2.5 x 10 5 Any of the aforementioned methods of the present invention, wherein the cell density is 1000 cells / ml. [The present invention 1016] Any of the aforementioned methods of the present invention, wherein the culture medium is selected from the group consisting of IPS-Brew, E8, StemFlex, mTeSR1, and PluriSTEM. [The present invention 1017] The method of claim 1016, wherein the culture medium is iPSC-Brew. [The present invention 1018] Any of the aforementioned methods of the present invention, wherein the culture media of steps (i) and (iii) are essentially the same. [The present invention 1019] Any of the methods of the present invention, wherein the temperature of the culture medium is about 30 to 50°C, about 35 to 40°C, about 36 to 38°C, or about 37°C, preferably 37°C. [The present invention 1020] Any of the methods of the preceding invention, wherein steps (i)-(iv) or (i)-(v) are repeated 1, 2, 3, 4, 5, at least 5, or at least 10 times. [The present invention 1021] Any of the methods of the present invention, wherein the pluripotent stem cells are selected from the group consisting of induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), parthenogenetic stem cells (pPSCs), and nuclear transfer-derived PSCs (ntPSCs). [The present invention 1022] The method of claim 1020, wherein the PSCs maintain pluripotency after each repetition of steps (i) through (iv) or (i) through (v). [The present invention 1023] Any of the aforementioned methods of the present invention, wherein the pluripotent stem cells are TC-1133 cells. [The present invention 1024] Any of the methods of the present invention, wherein the aggregates of step (ii) have an average diameter of about 180 μm to about 250 μm, preferably about 200 μm to about 250 μm, and most preferably about 200 μm. [The present invention 1025] Any of the methods of the present invention, wherein the aggregates are dissociated in step (ii) for at least about 1 minute, at least about 2 minutes, at least about 3 minutes, at least about 5 minutes, at least about 10 minutes, 1 to 20 minutes, about 10 to about 20 minutes, about 10 to about 15 minutes, or up to about 15 minutes, preferably about 15 minutes. [Brief explanation of the drawings]

[0031] The invention will be better understood by reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which: [Figure 1]An exemplary embodiment of the method of the present invention is shown. The method described with reference to Figure 1 is also implemented in Examples 1 and 2. This figure shows a starter culture followed by two repeated cycles or two cell passaging cycles. Prior to switching to suspension culture, PSCs, such as iPSCs, are cultured in standard cell culture flasks coated with Biolaminin 521-MX dissolved in IPS-Brew. To initiate suspension culture, PSCs are dissociated from the cell culture flask by adding a cell dissociation agent, here versene, and then used to inoculate a bioreactor, in this case at a seeding density of 2.5 x 10 cells / ml in a total volume of 13 ml. These cells are cultured in culture medium, e.g., iPS-Brew, supplemented with 10 μM ROCKi, e.g., Y27632, for approximately two days. After two days, a medium change to culture medium, e.g., iPS-Brew, without ROCKi, is initiated. Preferably, on day 4 or 5, when the aggregate size reaches approximately 200-250 μm, ROCKi (here, 10 μM Y27632) is added 2-4 hours (2 hours in Examples 1 and 2) before the dissociation step. This corresponds to step (i) of the method of the present invention and can also be recognized as the start of cycle 1 of cell passaging. One cycle may include steps (i) to (iv) and, optionally, step (v) of the method of the present invention. Next, (automated) dissociation (step (ii) of the method of the present invention) is performed: Examples 1 and 2 provide such an exemplary method for dissociation: First, the cells are washed twice with versene, which involves stopping agitation for approximately 2 minutes, removing the medium to approximately 2 ml, adding versene to 10 ml, and starting agitation (300 rpm, downward) for 10 seconds. Agitation is again stopped for approximately 2 minutes, removing the medium to 2 ml, and adding 3 ml of versene. The actual dissociation of the cell aggregates is then carried out by stirring at 600 rpm for up to 15 minutes until dissociation is complete. The cells may then be counted. The Versene solution is then diluted by adding an excess volume of fresh iPS-Brew. This dilution corresponds to step (iii) of the method of the present invention.Next, the passaged PSCs (preferably at a concentration of about 2-5 x 10 cells / ml after dilution) are cultured for 2 days, up to day 6, in a culture medium, such as iPS-Brew, supplemented with 10 µM ROCKi, e.g., Y27632 (step (iv) of the method of the present invention). On day 6, medium exchange with a culture medium, such as IPS-Brew, without ROCKi, begins (optional step (v) of the method of the present invention). This may be considered the end of cycle 1 of cell passaging. On day 8-9, the next iteration of cell passaging (cycle 2) begins: ROCKi is added 2-4 hours before the dissociation step. This corresponds to step (i) of the method of the present invention. Next, automated dissociation (step (ii) of the method of the present invention) and passaging (step (iii) of the method of the present invention) are performed. Next, the passaged PSCs are cultured for 2 days in iPS-Brew supplemented with 10 µM ROCKi, e.g., Y27632. Subsequent steps of passaging and culturing can continue. [Figure 2] 1 shows the aggregate size on the last day of each passage obtained by culturing as performed in Example 1 and as described for an exemplary embodiment of the method described with reference to FIG. 1. Each data point represents the value of one vessel. The average value is represented by a line. [Figure 3] Figure 1 shows the growth rates of individual passages for the cultures performed in Example 1. Data points represent the values ​​for one vessel. Connected lines represent the average values ​​for each passage. Passages 6 and 8 lasted 3 days, while the other passages lasted 4-5 days. [Figure 4] Figure 1 shows the cumulative fold change over the long-term suspension culture carried out in Example 1. The cumulative fold change was calculated using the starting cell number and each passage ratio during the passaging period. [Figure 5] This shows the expression of pluripotency-related genes at the end of passaging iPSCs treated with ROCKi, as performed in Example 1: OCT4 (left), TRA-1-60 (center), and OCT4 / TRA-1-60 (right). Mean values ​​± SD. [Figure 6]This shows the expression of pluripotency-related genes at the end of the passage of iPSCs treated with TZV, as performed in Example 1: OCT4 (left), TRA-1-60 (center), and OCT4 / TRA-1-60 (right). Mean values ​​± SD. [Figure 7] This shows the cumulative fold change over the long-term suspension culture carried out in Example 2. The cumulative fold change was calculated using the starting cell number and each passage ratio during the passage period. [Figure 8] Expression of pluripotency-associated genes at the end of the passaging performed in Example 2 is shown: OCT4 (left), NANOG (center left), LIN28 (center), OCT4 / NANOG (center right), and OCT4 / LIN28 (right). Mean ± SD. [Figure 9] iPSC morphology is shown. As performed in Example 3, iPSCs were switched from adherent culture (day 0) to suspension cell culture (days 1-4). On day 4, aggregates were dissociated using Versene for passaging (day 4, 3-8 min). Scale bar: 200 μm. [Figure 10] The aggregate size of iPSCs with and without pretreatment before and after cell dissociation, as performed in Example 4, is shown at passage 0, day 4 (left bar) and passage 1, day 3 (right bar). [Figure 11] The proliferation rates (fold change) of iPSCs pretreated with ROCKi before and after cell dissociation, as performed in Example 4, and those not pretreated, are shown at passage 0, day 4 (left bar), passage 1, day 3 (center bar), and passage 1, day 5 (right bar). [Figure 12] The figures show the expression rates of pluripotency markers in iPSCs pretreated with ROCKi before and after cell dissociation, as performed in Example 4, and iPSCs not pretreated, at passage 0, day 4 (left bar), passage 1, day 3 (middle bar), and passage 1, day 5 (right bar). The pluripotency markers analyzed were OCT4 (FIG. 12A), NANOG (FIG. 12B), and TRA-1-60 (FIG. 12C). [Figure 13]The morphology of cell aggregates at various time points at the end of each passage carried out in Example 5 (day 4 of p0, day 5 of p1, day 5 of p2, and day 4 of p3) is shown. [Figure 14] 1 shows aggregate sizes on each day during various passage periods for the cell growth shown in Example 5. [Figure 15] The proliferation rate (left axis, circles) and cell concentration (right axis, squares) at the end of all passages in Example 5 are shown. [Figure 16] 1 shows the expression of pluripotency-associated genes in iPSCs at the indicated time points for various passages in Example 5. DETAILED DESCRIPTION OF THE INVENTION

[0032] Detailed Description of the Invention The present invention is described in detail below and is further illustrated by the accompanying examples and figures.

[0033] In the present invention, it has been successfully demonstrated that PSCs can be switched from adherent cell culture ("starter culture") to continuous suspension culture in a bioreactor. Surprisingly, it was discovered that (a) the addition of a Rho-associated protein kinase (ROCK) inhibitor prior to cell dissociation increases cell viability and yield and promotes the maintenance of PSC pluripotency (see, e.g., Example 4), and (b) after diluting the cell dissociation reagent, PSCs can be cultured and expanded in medium still containing the cell dissociation reagent (see, e.g., Examples 1, 2, and 3). Furthermore, it was surprisingly discovered that (c) a chelating agent, such as a solution containing EDTA (ethylenediaminetetraacetic acid salt), can be used to dissociate pluripotent stem cell (PSC) aggregates (see Examples 1 and 2). Example 5 highlights that the present invention can be scaled up more than 30-fold without further modification. Therefore, the present invention enables automated culture of PSCs in a closed system, thereby reducing the number of manual operations, such as transferring PSCs from a bioreactor to a centrifuge during cell passaging. Therefore, the method of the present invention is easier, faster, and cheaper than conventional culture systems, and enables further automation of PSC production. Because the method of the present invention can be performed in a closed system as described above, it has the additional advantage of being perfectly suited for establishing a GMP-compliant stem cell manufacturing process.

[0034] Before continuous and automated expansion of PSCs in a bioreactor can begin, the PSCs must preferably be transferred to the bioreactor (see also Figure 1). Culturing PSCs in adherent culture is within the knowledge of one skilled in the art. For example, 0.9 μg / cm of iPSCs dissolved in a culture medium suitable for PSCs, such as iPSC-Brew medium, may be used. 2PSCs may be cultured in T25 / T75 culture flasks coated with Biolaminin 521-MX or other ECM proteins. PSCs derived from adherent cultures may also be used to initiate suspension cultures. Cells may be dissociated from the flask using a cell dissociation agent such as EDTA and transferred to culture medium containing ROCKi. Preferably, cell aggregates consisting of 2-10 cells are present. These dissociated PSCs may then be used to inoculate a bioreactor. The preferred cell concentration at the start of the method of the present invention is approximately 2.5 x 10 5 The cells are then cultured in suspension with continuous stirring to avoid settling and / or adhesion of the PSCs to the bottom of the bioreactor.

[0035] After inoculation, the cells are preferably cultured in a cell culture medium containing ROCKi for about 2 days to form cell aggregates. After the formation of cell aggregates, the medium may be changed to a cell culture medium that is essentially free of ROCKi, or in other words, a cell culture medium that is neither supplemented nor containing ROCKi.

[0036] PSCs can be passaged for the first time when the cell density and / or cell aggregate size reach a level where adequate nutrient supply is no longer possible (e.g., diameters of approximately 180-250 μm, preferably 200 μm). Initially, ROCKi is added to the culture medium, preferably 2-4 hours before dissociation of the aggregates. After preincubation of the cell aggregates in cell culture medium containing ROCKi, the cells may be washed once or twice with a cell dissociation agent. Washing may involve stopping the agitation of the cell aggregates in the bioreactor and allowing them to settle by gravity. The culture medium or cell dissociation agent may then be removed, preferably by aspiration, and replaced with (fresh) cell dissociation reagent. After addition, the cell aggregates may be agitated again, preferably at approximately 300 rpm for approximately 10 seconds, followed by another wash cycle. After two washing cycles with the cell dissociation reagent, the PSCs can be maintained in the cell dissociation reagent, preferably with continuous stirring at a high agitation speed, e.g., 600 rpm, until a suspension of small aggregates (approximately 5-50 cells) forms. The dissociated PSCs can then be used to inoculate another bioreactor by transferring a portion of the cells to another bioreactor, preferably followed by dilution with the addition of an excess volume of culture medium. Alternatively, or in addition, the dissociated PSCs can be diluted in the same bioreactor, i.e., without any cell transfer outside the closed system of the bioreactor. Alternatively, or in addition, a portion of the PSCs can be removed for clinical application, and the remaining PSCs can be used to inoculate the same bioreactor. At this point, the passaging is complete. Passaging can be repeated as outlined herein, thus enabling continuous propagation of PSCs at low cost and high yields. Figure 1 shows an exemplary embodiment of the method of the present invention, including a starter culture.

[0037] The present invention therefore relates to a method for expanding (induced) pluripotent stem cells (PSCs) in suspension culture in a bioreactor, the method comprising the following steps: (i) adding an inhibitor of ROCK (ROCKi) to pluripotent stem cells cultured in suspension in a bioreactor; (ii) adding a cell dissociation agent, thereby dissociating the pluripotent stem cell aggregates; (iii) diluting the cell dissociation agent added in step (ii) by adding an excess volume of culture medium sufficient to reduce the concentration of the cell dissociation agent to a concentration at which cell aggregates can reform; and (iv) culturing the mixture obtained in step (iii) under suitable conditions that allow proliferation of PSCs.

[0038] The method described herein may be considered a repeated batch of PSC passaging in a continuous and / or automated process, preferably in a closed system such as a bioreactor. This passaging method reduces the number of manual operations that can introduce lot-to-lot variation or contamination. As used herein, the terms "passage" and "passaging" refer to a process of subculturing adherent cells, in which cell adhesion is disrupted and cell density (number of cells per unit volume or unit area) is reduced by the addition of fresh medium. Thus, the present invention also relates to a method for passaging (induced) pluripotent stem cells (PSCs) in suspension culture in a bioreactor, comprising the following steps: (i) adding an inhibitor of ROCK (ROCKi) to pluripotent stem cells cultured in suspension in a bioreactor; (ii) adding a cell dissociation agent, thereby dissociating the pluripotent stem cell aggregates; (iii) diluting the cell dissociation agent added in step (ii) by adding an excess volume of culture medium sufficient to reduce the concentration of the cell dissociation agent to a concentration at which cell aggregates can reform; and (iv) culturing the mixture obtained in step (iii) under suitable conditions that allow proliferation of PSCs.

[0039] As outlined herein, PSCs may be passaged repeatedly, thus allowing the methods of the present invention to allow for sequential steps (expansion) of PSCs in a cascade-like process. Thus, steps (i)-(iv) or (i)-(v) may be repeated once, twice, three times, four times, five times, at least five times, or at least ten times. As shown in Examples 1 and 2 and Figures 5, 6, and 8, PSCs maintain pluripotency after each repetition of steps (i)-(iv) or (i)-(v) of the methods of the present invention for extended periods of time, i.e., for at least 49 days and 10 passages as shown in Example 2. Thus, PSCs preferably maintain pluripotency after each repetition of steps (i)-(iv) or (i)-(v).

[0040] The term "pluripotent stem cells" (PSCs), as used herein, refers to any cell that has the potential to differentiate into any cell type in the body. Thus, pluripotent stem cells offer the unique opportunity to differentiate into essentially any tissue or organ. Currently, the most commonly used pluripotent cells are embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs). Human ESC lines were first established by Thomson and coworkers (Thomson et al. (1998), Science 282:1145-1147). Research on human ESCs has recently enabled the development of a new technology for reprogramming somatic cells into ES-like cells. This technology was developed by Yamanaka and coworkers in 2006 (Takahashi & Yamanaka (2006), Cell, 126:663-676). The resulting induced pluripotent cells (iPSCs) exhibit behavior very similar to ESCs and, importantly, also have the potential to differentiate into any cell type in the body. Another example of pluripotent stem cells that can be used in the present invention are parthenogenetic (PG) (embryonic) stem cells, which can be readily derived, for example, from blastocysts that develop after activation of unfertilized oocytes in vitro, in both mice and humans (see, in this regard, e.g., Espejel et al, Parthenogenetic embryonic stem cells are an effective cell source for therapeutic liver repopulation, Stem Cells. 2014 Jul;32(7):1983-1988 or Didie et al, Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest. 2013 Mar;123(3):1285-98).Another example of suitable pluripotent stem cells that can be used in the present invention is nuclear transfer-derived PSCs (ntPSCs; see Kang et al., "Improving Cell Survival in Injected Embryos Allows Primed Pluripotent Stem Cells to Generate Chimeric Cynomolgus Monkeys," Cell Reports Volume 25, Issue 9, 27 November 2018, Pages 2563-2576). However, in the present invention, it is preferred that these pluripotent stem cells are not produced using a process that involves modifying the genetic identity of human germ lines or using human embryos for industrial or commercial purposes. The pluripotent stem cells are preferably of primate origin, including, but not limited to, those derived from mice, rats, felines, canines, bovines, equines, monkeys, or humans, and more preferably, those derived from humans.

[0041] For example, suitable induced PSCs can be obtained from the NIH Human Embryonic Stem Cell Registry, the European Bank of Induced Pluripotent Stem Cells (EBiSC), the Stem Cell Repository of the German Heart and Cardiovascular Research Center (DZHK), or the American Type Culture Collection (ATCC), to name just a few sources. Induced pluripotent stem cells are also available for commercial use, for example, from the NINDS Human Sequence and Cell Repository (https: / / stemcells.nindsgenetics.org), which is managed by the National Institute of Neurological Disorders and Stroke (NINDS) and provides a wide range of human cell resources to academic and industrial researchers. One example of a suitable cell line that can be used in the present invention is cell line TC-1133, which is an induced (unedited) pluripotent stem cell derived from umbilical cord blood stem cells. This cell line can be obtained, for example, directly from NINDS (USA). Preferably, TC-1133 is GMP-compliant. Other exemplary iPSC cell lines that may be used in the present invention include, but are not limited to, Gibco™ human episomal iPSC line (Order No. A18945, Thermo Fisher Scientific), or iPSC cell lines available from ATCC ACS-1004, ATCC ACS-1021, ATCC ACS-1025, ATCC ACS-1027, or ATCC ACS-1030.Alternatively, one skilled in reprogramming can readily generate suitable iPSC lines using known protocols such as those described by Okita et al., "A more efficient method to generate integration-free human iPS cells" Nature Methods, Vol. 8 No. 5, May 2011, pages 409-411 or Lu et al. "A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells", Biomaterials 35 (2014) 2816e2826.

[0042] As described herein, the (induced) pluripotent stem cells used in the present invention can be derived from any suitable cell type (for example, from stem cells such as mesenchymal stem cells or epithelial stem cells, or differentiated cells such as fibroblasts), and from any suitable source (body fluid or tissue).Examples of such sources (body fluid or tissue) include, to name just a few, umbilical cord blood, skin, gums, urine, blood, bone marrow, any compartment of the umbilical cord (for example, the amniotic membrane or Wharton's gel of the umbilical cord), the umbilical cord-placental junction, placenta, or adipose tissue.In one example, CD34-positive cells are isolated from umbilical cord blood by, for example, magnetic cell separation using an antibody that specifically targets CD34, followed by reprogramming as described in Chou et al. (2011), Cell Research, 21:518-529. Baghbaderani et al. (2015), Stem Cell Reports, 5(4):647-659, demonstrate that the iPSC generation process complies with Good Manufacturing Practice regulations to generate the cell line ND50039.

[0043] Thus, the pluripotent stem cells preferably meet the requirements of Good Manufacturing Practices for Pharmaceuticals.

[0044] The terms "expanding" or "expansion" of PSCs or iPSCs described herein refer to an increase in cell number through cell division. The method of the present invention may further include a step of expanding PSCs. Cell expansion may be performed in step (iv) of the method of the present invention, in step (v) of the method of the present invention, or in step (iv) and in step (v) of the method of the present invention, preferably in step (v) of the method of the present invention. In one embodiment, step (iv) comprises culturing the mixture obtained in step (iii) under appropriate conditions that allow the proliferation of PSCs, thereby expanding the PSCs. In one embodiment, step (v) comprises replacing the medium with a medium essentially free of ROCKi, thereby expanding the PSCs. The step of expanding PSCs may relate to the period between adding an inhibitor of ROCK (ROCKi) to pluripotent stem cells cultured in suspension in a bioreactor (see step (i) of the method of the present invention) and diluting the cell dissociation agent added in step (ii) by adding an excess volume of culture medium sufficient to reduce the concentration of the cell dissociation agent to a concentration at which cell aggregates can reform (see step (iii) of the method of the present invention), and preferably lasts for about 2 to about 6 days, preferably about 3 to about 5 days, preferably about 3.5 to about 4.5 days, or more preferably about 4 days. In this context, "about" may relate to a delay of 8 hours or less, 4 hours or less, 2 hours or less, or 1 hour or less.

[0045] As used herein, the term "suspension culture" is a type of cell culture in which single cells or small cell aggregates are allowed to function and multiply in an agitated growth medium, thus forming a suspension (see chemical definition: "small solid particles suspended in a liquid"). This is in contrast to adherent culture, in which cells are allowed to adhere to a cell culture vessel that may be coated with proteins of the extracellular matrix (ECM). In suspension culture, preferably, ECM proteins are not added to the cells and / or the culture medium.

[0046] As used herein, the terms "aggregate" and "cell aggregate" may be used interchangeably, and refer to a plurality of (induced) pluripotent stem cells in which cell-to-cell binding occurs through cell-to-cell interactions (e.g., biological adhesion to one another). Biological adhesion may be, for example, via surface proteins such as integrins, immunoglobulins, cadherins, selectins, or other cell adhesion molecules. For example, cells may spontaneously associate in suspension to form cell-to-cell adhesions (e.g., self-assembly), thereby forming aggregates of PSCs. In some embodiments, cell aggregates may be substantially homogeneous (i.e., primarily comprising the same type of cells). In some embodiments, cell aggregates may be heterogeneous (i.e., comprising multiple types of cells).

[0047] In some embodiments, the aggregates in step (ii) of the method of the present invention have an average diameter of about 150 to about 800 μm in size. In some embodiments, the aggregates in step (ii) of the method of the present invention have an average diameter of at least about 800 μm in size. In some embodiments, the aggregates in step (ii) of the method of the present invention have an average diameter of at least about 600 μm in size. In some embodiments, the aggregates in step (ii) of the method of the present invention have an average diameter of at least about 500 μm in size. In some embodiments, the aggregates in step (ii) of the method of the present invention have an average diameter of at least about 400 μm in size. In some embodiments, the aggregates in step (ii) of the method of the present invention have an average diameter of at least about 300 μm in size. In some embodiments, the aggregates in step (ii) of the method of the present invention have an average diameter of at least about 200 μm in size. In some embodiments, the aggregates in step (ii) of the method of the present invention have an average diameter of at least about 150 μm in size. In a preferred embodiment, the aggregates in step (ii) of the method of the invention have an average diameter of about 300 to about 500 μm in size. In a preferred embodiment, the aggregates in step (ii) of the method of the invention have an average diameter of about 150 to about 300 μm in size.

[0048] It is preferable to avoid the formation of large PSC aggregates. This is because a diameter greater than approximately 300 μm can lead to cell necrosis due to limited nutrient and gas diffusion to the tissue / aggregate center. Ultimately, uncontrolled differentiation can occur, especially in large PSC aggregates. Therefore, it is important to periodically dissociate aggregates into single cells at each passage. As shown in the Examples, the method of the present invention solves this problem in a simple manner. In the present invention, an average diameter of approximately 180 to approximately 250 μm, preferably approximately 200 to approximately 250 μm, and ideally approximately 200 μm before dissociation of cell aggregates is shown to be the best compromise between pluripotency and cell yield. Therefore, preferably, the aggregates in step (ii) of the method of the present invention have a diameter of approximately 180 to approximately 250 μm, more preferably approximately 200 to approximately 250 μm, and most preferably approximately 200 μm.

[0049] As used herein, the terms "reactor" and "bioreactor" may be used interchangeably and refer to a closed culture vessel configured to provide a dynamic fluid environment for cell culture. Examples of stirred tank bioreactors include, but are not limited to, stirred tank bioreactors, wave / rocking bioreactors, top-bottom stirred bioreactors (i.e., stirred reactors involving piston movement), spinner flasks, shaker flasks, shaker bioreactors, paddle mixers, and vertical wheel bioreactors. Stirred tank bioreactors may be configured to accommodate cell culture volumes ranging from approximately 2 mL to 20,000 L. Preferred bioreactors may have volumes of up to 50 L. Exemplary bioreactors suitable for the methods of the present invention are the ambr15® bioreactor or the UniVessel® bioreactor, both available from Sartorius Stedim Biotech (the latter available in versions ranging from 0.5 to 10 L in volume, for example). The pH of the culture medium may be controlled by the bioreactor, preferably by CO2 supply, and may be kept in the range of 6.6 to 7.6, preferably about 7.4.

[0050] In some embodiments, the volume of the culture vessel in the bioreactor is about 50 mL to about 20,000 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 50 mL to about 2,000 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 50 mL to about 200 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 50 mL to about 100 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 50 mL to about 50 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 50 mL to about 20 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 50 mL to about 10 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 50 mL to about 1 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 100 mL to about 10 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 100 mL to about 5 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 150 mL to about 1 L. In some embodiments, the volume of the culture vessel in the bioreactor is about 1 L to about 1,000 L.

[0051] Particularly preferred are bioreactors in which the minimum and maximum cell culture volumes differ by 5-fold or even 10-fold, i.e., bioreactors that can be understood to enable scale-up within the same bioreactor. Such bioreactors can allow PSC growth to begin in a relatively small volume, e.g., 200 mL. If the cell dissociation reagent is diluted by adding a 5-fold excess volume of culture medium, e.g., cell culture medium, this results in a final volume of approximately 1 L after the first passage. If, after cell growth, the cells are then dissociated again and subsequently an excess volume of culture medium is added, the volume increases to 5 L, e.g., after the second cell passage. Thus, bioreactors that accommodate both relatively small and large volumes allow cells to be passaged several times in the same bioreactor without any manual manipulation (in a cascade-like process), e.g., by removing a portion of the cells and using this portion to inoculate another bioreactor, while using the remaining portion of the cells to re-inoculate the original bioreactor (a "repeated batch strategy" or "cascade-like process"). This allows for approximately 1000-fold expansion of PSCs without any manual intervention such as transferring cells in and out of the bioreactor, which has the advantage of minimizing the risk of contamination and facilitates PSC growth under GMP conditions.

[0052] The methods of the invention may be suitable for use on a large scale (e.g., 1 L to 1000 L). In a preferred embodiment, for large-scale production, the bioreactor suitable for use in the second or subsequent culture period is a larger reactor than the bioreactor used for the initial culture and dissociation. In a preferred embodiment, multiple bioreactors are inoculated in parallel for use in the second or subsequent culture period, thereby facilitating a series of parallel passagings.

[0053] The bioreactor may be a stirred or agitated bioreactor. Preferably, the agitator speed is optimized for each individual bioreactor. Those skilled in the art are skilled in selecting an appropriate agitator speed for culturing PSCs and dissociating PSC cell aggregates. The agitator speed for culturing PSCs is preferably slow, e.g., in the range of about 150 to about 450 rpm, preferably about 300 rpm. This contrasts with speeds suitable for promoting cell dissociation, which may require faster speeds, e.g., in the range of about 450 to about 750 rpm, preferably about 600 rpm. During washing, the agitation speed is preferably in the range of about 150 to about 450 rpm, preferably about 300 rpm. Thus, in one embodiment, the bioreactor is an ambr15 bioreactor manufactured by Sartorius Stedim, with an agitation speed of 300 rpm for cell growth and 600 rpm for cell dissociation.

[0054] As used herein, the terms "dissociate" and "dissociation" refer to the process of separating aggregated cells from one another. For example, during dissociation, cell-cell interactions and cell-cell interactions between cells may be disrupted, thereby breaking up the cells in the aggregate.

[0055] As used herein, the term "cell dissociation agent" or "cell dissociation reagent" can be used interchangeably, and refer to a reagent or a solution containing one or more reagents that separate cells from each other, such as a chelating agent.For example, a dissociation reagent can break the bonds between cells, thereby preventing cells in suspension from aggregating.For example, a dissociation reagent can be a chelating agent, and a chelating agent can cause the separation of molecules, for example, by chelation, which interferes with calcium- or magnesium-dependent adhesion molecules, thereby weakening or disrupting the bond formation between cell adhesion proteins.

[0056] Therefore, the dissociation reagent is preferably a chelating agent. As used herein, "chelating agent" refers to a Ca 2+or Mg 2+ The chelate may be an (organic) compound, peptide, or protein that chelates divalent cations such as . Chelation is a type of binding of ions and molecules to metal ions. Chelation involves the formation or existence of two or more separate coordinate bonds between a multidentate (multiply bonded) ligand and a single central atom.

[0057] The chelating agent may be selected from the group consisting of ethylenediaminetetraacetate (EDTA), ethyleneglycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), iminodisuccinic acid (IDS), polyaspartic acid, ethylenediamine-N,N'-disuccinic acid (EDDS), citrate, citric acid, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), and methylglycine diacetic acid (MGDA). The chelating agent may be ethylenediaminetetraacetate (EDTA). The chelating agent may be ethyleneglycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA). The chelating agent may be iminodisuccinic acid (IDS). The chelating agent may be polyaspartic acid. The chelating agent may be ethylenediamine-N,N'-disuccinic acid (EDDS). The chelating agent may be citrate. The chelating acid may be citric acid. The chelating agent may be 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA). The chelating agent may be methylglycine diacetic acid (MGDA). Preferably, the chelating agent is EDTA. The commercially available EDTA-containing "Versene" solution available from ThermoFisher Scientific is an exemplary preferred dissociation reagent.

[0058] The final concentration of the chelating agent used in step (ii) may be at least 100 μM, in the range of about 100 to about 1000 μM, in the range of about 250 to about 750 μM, in the range of about 400 to about 600 μM, or about 500 μM, preferably about 500 μM. The final concentration of the chelating agent used in step (ii) may be at least 100 μM EDTA, in the range of about 100 to about 1000 μM EDTA, in the range of about 250 to about 750 μM EDTA, in the range of about 400 to about 600 μM EDTA, or about 500 μM EDTA, preferably about 500 μM EDTA.

[0059] As described herein, the use of proteolytic enzymes has a negative impact on the cell viability and pluripotency of PSCs and is preferably avoided. Therefore, the cell dissociation agent is preferably essentially free of enzymes such as proteases. In this context, "essentially free of enzymes" may refer to a cell dissociation agent to which no enzymes, preferably proteolytic enzymes such as trypsin, pepsin, etc., have been added. Thus, "essentially free of enzymes" may exclude enzymes or solutions containing enzymes, including Accutase, Accumax, trypsin, TrypLE Select, and collagenase B.

[0060] As used herein, the terms "dissociated" and "dissociated aggregate" refer to a single cell or a cell aggregate or cell cluster that is smaller than the original cell aggregate (i.e., smaller than the aggregate prior to dissociation, e.g., as found in step (i)). For example, the dissociated aggregate may comprise about 50% or less of the surface area, volume, or diameter of the cell aggregate prior to dissociation. The dissociated aggregate may consist of cell aggregates having 2-10 PSCs or having 1-10 PSCs. Preferably, the dissociated cell aggregate has a diameter of about 25 μm to about 130 μm, more preferably about 80 μm to about 100 μm, after step (iii) of the method of the present invention.

[0061] The size of the resulting dissociated aggregates can be controlled by the length of time the cell dissociation reagent is left undiluted in step (ii) of the method of the invention. Thus, aggregates are preferably dissociated in step (ii) for at least about 1 minute, at least about 2 minutes, at least about 3 minutes, at least about 5 minutes, at least about 10 minutes, 1 to 20 minutes, about 10 to about 20 minutes, about 10 to about 15 minutes, or up to about 15 minutes, preferably about 15 minutes.

[0062] As outlined herein, one advantage of the present invention is that removal of the dissociation reagent is not necessary, allowing further culture of PSCs without the need for a washing step, e.g., centrifugation or other mechanical manipulation of the cells. Thus, PSCs remain intact and can be cultured in medium containing the diluted dissociation reagent after dissociation, thereby reforming cell aggregates. This avoids error-prone and contamination-prone manual procedures, which are particularly desirable under GMP conditions. The dilution step (iii) of the method of the present invention reduces the concentration of the cell dissociation agent to a concentration at which cell aggregates can reform, thereby terminating the cell dissociation reaction. If the cell dissociation agent is a chelating agent, the excess volume of medium added in step (iii) can provide a sufficient amount of ions to saturate the chelating agent, allowing ions from the culture medium being added to replace ions bound by the chelating agent in step (ii). When EDTA is used as a chelating agent, preferably at a final concentration of about 500 μM, the dissociation reagent added in step (ii) can be diluted with a 5-fold excess volume of culture medium. Preferably, the concentration of the dissociation agent in the mixture obtained after dilution in step (iii) is about 100 μM or less, about 95 μM or less, about 90 μM or less, about 80 μM or less, about 70 μM or less, in the range of about 100 to about 1 μM, or in the range of about 90 to about 1 μM. When the dissociation reagent is EDTA, the concentration of the dissociation agent in the mixture obtained after dilution in step (iii) is about 100 μM or less EDTA, about 95 μM or less EDTA, about 90 μM or less EDTA, about 80 μM or less EDTA, about 70 μM or less EDTA, in the range of about 100 to about 1 μM EDTA, or in the range of about 90 to about 1 μM EDTA.

[0063] As used herein, the term "excess volume" may relate to a volume that is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 7.5-fold, at least 10-fold, at least 20-fold, or at least 30-fold greater than the amount of dissociation reagent added in step (ii).

[0064] Rho-associated protein kinase (ROCK) is a member of the AGC (PKA / PKG / PKC) family of serine-threonine kinases. It is primarily involved in regulating cell shape and motility by acting on the cytoskeleton. ROCKs (ROCK1 and ROCK2) are found in mammals (human, rat, mouse, cow), zebrafish, Xenopus, invertebrates (C. elegans, mosquito, Drosophila), and chicken. Human ROCK1 has a molecular mass of 158 kDa and is a major downstream effector of the small GTPase RhoA. Mammalian ROCKs consist of a kinase domain, a coiled-coil region, and a pleckstrin homology (PH) domain, which inhibits the kinase activity of ROCK by autoinhibitory intramolecular folding in the absence of RhoA-GTP. ROCK1 is primarily expressed in the lung, liver, spleen, kidney, and testis, whereas ROCK2 is primarily distributed in the brain and heart. Protein kinase C and Rho-associated protein kinase are involved in regulating calcium ion uptake, which then stimulates myosin light chain kinase, resulting in contraction.

[0065] ROCK inhibitors (ROCKi) are well known to those skilled in the art. Examples of ROCKi include, but are not limited to, AS1892802, fasudil hydrochloride, GSK 269962, GSK 429286, H 1152, HA 1100, OXA 06, RKI 1447, SB 772077B, SR 3677, TC-S 7001, thiazovivin, and Y27632. Preferably, the ROCKi is Y27632. The concentration of ROCKi, such as Y27632, is preferably in the range of 1-100 μM, 2-80 μM, 5-50 μM, 5-25 μM, or about 10 μM. Y27632 has the following structure 1: I have TIFF0007804327000001.tif59128.

[0066] Preferably, ROCKi is thiazovivin. The concentration of ROCKi such as thiazovivin is preferably in the range of 1 to 100 μM, 2 to 80 μM, 5 to 50 μM, 5 to 25 μM, or about 10 μM. Thiazovivin has the following structure 2: I have TIFF0007804327000002.tif49128.

[0067] A ROCK inhibitor may be added to the culture medium used in step (iii) of the method of the present invention to promote cell survival and cell reaggregation of PSCs (see, for example, Example 4). Therefore, the culture medium in step (iii) preferably contains ROCKi. Similarly, ROCKi is added to PSCs cultured in a bioreactor in step (i) of the method of the present invention. The addition of ROCKi may be performed about 2 to about 4 hours before step (ii) of the method of the present invention.

[0068] Continuous administration of ROCKi to PSC suspension cultures after aggregate (re)formation may reduce the yield of the PSC culture. Therefore, in one embodiment of the present invention, the culture medium is replaced with a medium essentially free of ROCKi, preferably after the PSCs have reformed aggregates. Therefore, the method of the present invention may further include step (v), i.e., replacing the medium with a medium essentially free of ROCKi. It may take up to three days for PSC aggregates to reform in suspension culture. Therefore, the culture medium used after dilution step (iii) of the method of the present invention preferably contains ROCKi for about one to about three days, preferably two days. In other words, step (iv) of the method of the present invention is carried out for about one to three days, preferably about two days. The medium replacement with a medium essentially free of ROCKi may begin after step (iii) of the method of the present invention, i.e., about one to three days, preferably about two days, after dilution of the cell dissociation agent.

[0069] In one embodiment of the present invention, the addition of an excess volume of culture medium in step (iii) reduces the number of cells in the culture medium to about 1 x 10 5 ~Approx. 1×10 6cells / ml, about 1.5 to about 7.5×10 5 cells / ml, approximately 2×10 5 ~Approx. 5×10 5 cells / ml, approximately 2×10 5 ~Approx. 3×10 5 cells / ml, or approximately 2.5 x 10 5 cells / ml.

[0070] PSCs cultured in suspension in a bioreactor are cultured in a culture medium. Culture media that allow PSC proliferation are known to those skilled in the art, including, but not limited to, IPS-Brew, iPS-Brew XF, E8, StemFlex, mTeSR1, PluriSTEM, StemMACS, TeSRTM2, Corning NutriStem hPSC XF Medium, Essential 8 Medium (ThermoFisher Scientific), and StemFit Basic02 (Ajinomoto Co. Inc.). In one example, the culture medium is IPS-Brew, available in GMP grade from Miltenyi Biotec (Germany). The culture medium used to culture cells before adding ROCKi in step (i) of the method of the present invention may be the same as the culture medium used to dilute the cell dissociation agent in step (iii) of the method of the present invention. Therefore, the culture media in steps (i) and (iii) of the method of the present invention may be essentially the same. The culture medium used in steps (iv) and (v) may also be the same as the culture medium used in steps (i) and (iii) of the method of the present invention.

[0071] In the methods of the present invention, the culture medium may be continuously exchanged using perfusion. Perfusion is characterized by the continuous exchange of reactor medium with fresh medium while maintaining cells in the vessel through a unique system (see also the review by Kropp et al., "Progress and challenges in large-scale expansion of human pluripotent stem cells," Process Biochemistry, Vol. 59, Part B, August 2017, Pages 244-254). Perfusion is an operating mode for biopharmaceutical production processes that achieves maximum cell density and productivity. In addition to the advantage of constantly supplying fresh nutrients and growth factors to perfused cells, potentially toxic waste products are washed away, ensuring more uniform conditions in the reactor. Furthermore, compared to repeated batch processes, perfusion processes facilitate process automation and improved feedback control of the culture environment, including DO, pH, and nutrient concentrations. Perfusion culture also supports the self-regulation ability of PSCs through endogenous factor secretion, and therefore may achieve a relatively stable physiological environment that ultimately reduces the need for supplementation of expensive medium components. Therefore, the culture medium may be continuously exchanged by perfusion in step (iv). The culture medium may be continuously exchanged by perfusion in step (v). The culture medium may be continuously exchanged by perfusion in steps (iv) and (v). Continuous medium exchange by perfusion with a culture medium essentially free of ROCKi can be used in step (iv) to exchange the medium for a medium essentially free of ROCKi. Thus, in one embodiment, step (iv) of the method of the present invention comprises culturing the mixture obtained in step (iii) under appropriate conditions that allow proliferation of PSCs, wherein the culture medium is exchanged for a medium essentially free of ROCKi by perfusion.

[0072] Another factor determining whether conditions are suitable for PSC proliferation is temperature, which is about 30-50°C, about 35-40°C, about 36-38°C, or about 37°C, preferably 37°C.

[0073] It should be noted that, as used herein, the singular forms "a," "an," and "the" include plural referents unless the context specifically dictates otherwise. Thus, for example, reference to "a reagent" includes one or more of such various reagents, and reference to "the method" includes reference to equivalent steps and methods known to those skilled in the art that may be modified or used in place of the methods described herein.

[0074] Unless otherwise specified, the term "at least" preceding a series of elements should be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by this invention.

[0075] The term "and / or" whenever used herein includes the meaning of "and", "or" and "all or any other combination of the elements connected by said term".

[0076] The terms "less than" or even "more than" do not include that particular value.

[0077] For example, less than 20 means fewer than a specified number. Similarly, "more than" or "greater than" means more than or above a specified number, for example, more than 80% means more than or above a specified number of 80%.

[0078] Throughout this specification and the claims that follow, unless the context dictates otherwise, the word "comprise," and variations such as "comprises" and "comprising," are understood to mean the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integers and steps or groups of integers and steps. As used herein, the term "containing" or "including," or sometimes, as used herein, the term "having," can be used in place of the term "comprising." As used herein, "consisting of" excludes any element, step, or ingredient not specified.

[0079] The term "including" means "including but not limited to." "Including" and "including but not limited to" are used interchangeably.

[0080] As used herein, the term "about" or "approximately" means within 20%, preferably within 15%, preferably within 10%, and more preferably within 5% of a given value or range. The term also includes the specific numerical value, i.e., "about 20" includes the numerical value 20.

[0081] It is to be understood that this invention is not limited to the particular methodology, protocols, materials, reagents, and substances, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[0082] All publications cited throughout the text of this specification, whether supra or infra, including all patents, patent applications, scientific publications, instruction manuals, etc., are hereby incorporated by reference in their entirety. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention. To the extent that material incorporated by reference contradicts or is inconsistent with this specification, the present specification shall take precedence over any such material.

[0083] The contents of all papers and patent documents cited herein are incorporated by reference in their entirety. [Example]

[0084] Experimental Example A further understanding of the present invention and its advantages will become apparent from the following experimental examples, which are provided for illustrative purposes only and are not intended to limit the scope of the invention in any way. material and method Unless otherwise specified, the following materials and methods were used in each example. General culture At passage number 0, 2.5 x 10 cells per vessel 5 Cells / ml was 13 ml, and 5 × 10 cells / vessel for all other passage numbers. 5 13 ml of cells / ml. Medium exchange: 62% exchange per day ·Cells: TC1133, NINDS Culture conditions: 37°C, pH 7.4, dO 23.8%, 300 rpm downward agitation. Cell passaging 1. Treat iPSC aggregates with Y27632 at a final concentration of 10 μM 2 hours before dissociation. 2. Wash twice with Versene: Stop stirring for 2 minutes, remove medium to 2 mL without disturbing the settled aggregates, add Versene to 10 mL, and begin stirring (300 rpm, downward) for 10 seconds. 3. Remove medium to 2 mL and add Versene to 5 mL as described in the washing step. 4. Stir at 600 rpm for up to 15 minutes until fully dissociated. Controls should be observed microscopically during the process to assess the degree of proper dissociation. 5. Reduce the stirring speed to 300 rpm. 6. Count the cells. 7. Transfer a volume of cell suspension to a new ambr15 vessel to achieve a seeding concentration of 2–5 × 10 5 cells / mL and thereby dilute the cell dissociation reagent by adding an excess volume (at least 5x) of iPS-Brew. material ambr15 Cell Culture 24 Disposable Bioreactor, Low Temperature, No Sparger, Part Number 001-2B81 StemMACS iPS-Brew XF, basal medium, order number: 130-107-086 StemMACS™ iPS-Brew XF 50x Supplement; Order Number: 130-107-087 ·ROCKi Y27632; Stemolecule Versene Solution, Catalog Number: 15040-033 Ambr15 bioreactor, Sartorius Stedim Nucleocounter NC-200 Type 900-0201 Cellavista cell imaging system Flow cytometer: BD LSR II custom-order system

[0085] Example 1: iPSCs maintain pluripotency in suspension culture for at least 8 passages and at least 43 days The aim of this experiment was to establish long-term cultures up to passage 8. To this end, we evaluated the impact of long-term suspension culture on iPSC quality. Furthermore, we tested the use of thiazovivin, another alternative ROCK inhibitor, and compared it with Y27632 during passaging of iPSCs in suspension.

[0086] result Aggregate size At the end of all passages except passage 0, the aggregates had developed to a size of approximately 200 μm (see FIG. 2). The size of aggregates treated with ROCKi and TZV was similar.

[0087] Cell count and proliferation rate The proliferation rate of iPSCs passaged with TZV was comparable to that of ROCKi-treated cells (see Figure 3). The proliferation rate was highest at passage 0, where the cell number increased approximately 14-fold. At passages 1 to 5, the proliferation rate was approximately 7-fold, and at passages 6 to 8, the proliferation rate was approximately 8-fold.

[0088] The cumulative proliferation rate of ROCKi-treated iPSCs calculated over the entire culture period shows exponential growth (see Figure 4). After 43 days, the cumulative expansion rate was 9.6 x 10 6 reached.

[0089] pluripotency ROCKi-treated iPSCs showed high expression of pluripotency-associated genes (OCT4, TRA-1-60) at the end of all passages analyzed (see Figure 5). TZV-treated iPSCs also showed high expression of pluripotency-associated genes at the end of passages 0, 2, and 3 (see Figure 6).

[0090] analysis iPSCs were cultured for 43 days and automatically passaged 8 times using the culture / passage strategy described herein. No significant differences were found between ROCKi and TZV treatments during passaging. iPSCs consistently maintained high quality: aggregate size at the end of passaging was approximately 200 μm. The expansion rate per passage was approximately 7-8 fold, with a cumulative expansion rate of approximately 1 × 10 after 43 days. 7 Importantly, expression of pluripotency-associated genes remained high even at passage 8.

[0091] summary Long-term culture of iPSCs in suspension was surprisingly successful for 43 days and 8 passages, demonstrating high-quality iPSCs up to passage 8. Most importantly, washing of iPSCs / removal of cell dissociation reagents after dissociation of cell aggregates was surprisingly not necessary to maintain high-quality suspension cultures for an extended period of time, here 8 passages and 43 days.

[0092] Example 2: iPSCs maintain pluripotency in suspension culture for at least 10 passages and at least 49 days Example 2 was carried out in the same manner as Example 1, except that the suspension culture, based on the inventive passaging / cell dissociation method of the present invention, was extended to 10 passages and 49 days.

[0093] result Cell count and proliferation rate The cumulative proliferation rate calculated over the entire culture period indicates exponential growth of iPSCs (see Figure 7). After 49 days, the cumulative expansion rate was 2.9 x 10 7 reached.

[0094] pluripotency Pluripotency-associated genes were highly expressed at the end of all passages analyzed (see Figure 8).

[0095] analysis iPSCs were cultured for 49 days and automatically passaged 10 times using the culture strategy of the present invention. The iPSCs maintained a consistent, high quality: the aggregate size at the end of each passage, which lasted 4-5 days, was a desirable size of around 200 μm. The proliferation rate was approximately 8-fold, with a cumulative increase of 2.9 × 10 7 Importantly, expression of pluripotency-associated genes remained very high (>95%) even at passage 10. Thus, these results validate the culture strategy.

[0096] summary For the first time, long-term culture of iPSCs in suspension was performed in ambr15 for 49 days and 10 passages. High-quality iPSCs were maintained up to passage 10.

[0097] Example 3: Morphological analysis of iPSCs passaged using the method of the present invention Example 3 was carried out similarly to Examples 1 and 2. On day 0, the adherent cell culture was switched to suspension culture. On day 4, the cell aggregates were dissociated. Samples were taken on day 0 (still as adherent culture), day 1, day 2, day 3, and day 4 (before and after cell dissociation). Figure 9 shows light microscope images of these samples containing iPSCs. The cells exhibit normal morphology, suggesting that diluting the dissociation reagent and continuing the culture does not have any negative impact on cell morphology.

[0098] Example 4: Effect of ROCKi pretreatment The aim of this example was to analyze the effect of ROCKi pretreatment on the passaging of iPSCs in suspension. Example 4 was carried out as in Examples 1 to 3, except that ROCKi pretreatment was carried out for 4 hours.

[0099] result Aggregate size As shown in Figure 10, on the day of passaging (day 4 of passage 0), the size of the aggregates of iPSCs to be pretreated with ROCKi was similar to that of iPSCs to be passaged without pretreatment (197.41 ± 75 μm for the former and 200.39 ± 64.05 μm for the latter). On day 3 after passaging, the aggregates with ROCKi pretreatment were larger than those without ROCKi pretreatment (162.06 ± 53 μm for the former and 113.8 ± 49.36 μm for the latter).

[0100] Growth rate As shown in Figure 11, on the day of passaging (day 4 of passage 0), the proliferation rate of iPSCs to be pretreated with ROCKi was similar to that of iPSC aggregates to be passaged without pretreatment (a 12.34-fold increase for the former and a 13.33-fold increase for the latter). On day 3 after passaging, the proliferation rate of iPSCs pretreated with ROCKi was higher than that of aggregates without ROCKi pretreatment (a 3.14-fold increase for the former and a 1.71-fold increase for the latter). The same was observed on day 5 after passaging (a 9.2-fold increase for the ROCKi pretreatment and a 5.08-fold increase for the non-pretreatment).

[0101] pluripotency As shown in Figure 12, on the day of passaging (day 4 of passage 0), the expression of pluripotency-associated markers in iPSCs to be pretreated with ROCKi and iPSCs to be passaged without pretreatment was comparable (97.8% OCT4, 96.9% NANOG, 99.3% TRA-1-60 in the former, and 98.4% OCT4, 97% NANOG, 99.2% TRA-1-60 in the latter). At day 3 after passage, ROCKi-pretreated iPSCs expressed higher levels of NANOG than aggregates without ROCKi pretreatment, and expression of OCT4 and TRA-1-60 was comparable (95.9% OCT4, 93.6% NANOG, and 99.1% TRA-1-60 in ROCKi-pretreated iPSCs, compared with 95.4% OCT4, 61.7% NANOG, and 95.2% TRA-1-60 in unpretreated iPSCs). At day 5 after passage, expression of pluripotency-associated markers was comparable in both conditions (94.4% OCT4, 81.8% NANOG, and 98.7% TRA-1-60 in ROCKi-pretreated iPSCs, compared with 95.2% OCT4, 92.4% NANOG, and 98.9% TRA-1-60 in unpretreated iPSCs).

[0102] analysis Pretreatment of iPSC aggregates with ROCKi before passaging increased aggregate size and proliferation rate in subsequent passages. Furthermore, ROCKi-pretreated cells showed elevated expression of NANOG at early subsequent passages, suggesting a beneficial effect on the pluripotent state of iPSCs. Collectively, these results suggest that pretreatment with ROCKi before passaging enhances the proliferation and quality of iPSCs in suspension culture.

[0103] Example 5: Scaling up of the method of the present invention Experimental design and progress: Passage number 0: ·Cell: TC1133 TL004, p4 ·Seeding conditions: 2.5×10 5 450 ml of cells / ml Medium change: Start on day 2, perfusion 60% Culture conditions: 37°C, pH 7.4, dO 23.8%, blade angle 45°, 120 rpm downward agitation (days 0–1) and 100 rpm downward agitation (days 1–4). Passage numbers 1-3: ·Seeding conditions: 2.5×10 5 320 ml of cells / ml Medium change: Start on day 2, set perfusion to 60% Culture conditions: 37°C, pH 7.4, dO 23.8%, blade angle 45°, 120 rpm downward agitation (days 0-1) and 100 rpm downward agitation (days 1-1 of subculture). Passage procedure: Two hours before passaging, iPSCs were treated with ROCKi (final concentration 10 μM). · The aggregates were washed twice with 0.5 mM EDTA by allowing the aggregates to settle to the bottom of the container (stirring was stopped for 2–5 min), aspirating the medium to 50 mL, and adding 200 mL of EDTA solution. As described in the washing step, aggregates were allowed to settle to the bottom of the vessel and the EDTA solution was aspirated to 50 mL. The aggregates were dissociated by adding 100 mL of EDTA solution and stirring at 200 rpm for up to 15 minutes. Once an adequate degree of dissociation was reached (small clumps of approximately 20 cells still remained), the agitation was slowed to 50 rpm and the cells were counted. The cell suspension in the vessel was reduced to the volume required to achieve the desired cell concentration. The required volume of iPS-Brew + 10 μM ROCKi was added to achieve the desired cell concentration. Cells were counted and cultured as described above. material Reagents and materials: StemMACS iPS-Brew XF, basal medium, order number: 130-107-086 StemMACS iPS-Brew XF 50x Supplement; Order Number: 130-107-087 ROCKi: Y27632 dihydrochloride; Tocris Catalog No. 1254 UltraPure 0.5M EDTA, pH 8.0; Catalog No. 15575020 Device Biostat B-DCU II: Type: BB-8841212 Tower 3: Type: BB-8840152 pH sensor: Hamilton; Easyferm Plus VP 120 Oxygen sensor: Hamilton; Oxyferm FDA VP 120 UniVessel 0.5L pH meter: Multi 3510 IDS; Xylem Analytics Germany GmbH ·pH-Elektrode:SenTix Micro 900P; WTW ·Nucleocounter NC-200 Type 900-0201 Cellavista Flow cytometer: CytoFlex; Beckman Coulter

[0104] result In this case, culture was performed in UniVessels for 18 days with frequent sampling. iPSCs were passaged three times. Well-formed aggregates were observed at every passage (Figure 13).

[0105] The aggregates were large at day 1 of passage 0, approximately 120 μm in size (Figure 14). At day 4 of passage 0, the aggregates reached a size of approximately 185 μm. At passages 1 to 3, the aggregates increased from approximately 100 μm on day 1 to approximately 200 μm (p1 and 2) or 180 μm (p3) on days 4 or 5. This is in good agreement with the data generated in the ambr15 line.

[0106] The proliferation rate after 4 days of culture at passage 0 was excellent, exceeding the desired 10-fold increase (Figure 15). The proliferation rate at passages 1 and 2 was approximately 6-fold. At passage 3, the proliferation rate was approximately 9-fold. These findings are consistent with long-term culture experiments with the ambr15 line, which also showed a lower proliferation rate at passages 1 and 2 compared to passage 0 and subsequent passages.

[0107] Pluripotency-associated genes were highly expressed in the inoculum. In suspension culture, pluripotency-associated markers were highly expressed in iPSCs at the end of all passages (Figure 16). Interestingly, there was a slight increase in OCT4 expression from inoculation to passage 3.

[0108] In this example, iPSCs were expanded in a 0.5 L UniVessel for 18 days while maintaining high culture quality. iPSCs were successfully passaged three times in the UniVessel without manual handling. The proliferation rate was good, with approximately 10-fold increases observed between passages 0 and 4. Aggregate size was approximately 100 μm on day 1 and reached the desired size of approximately 200 μm by the end of all passages. Importantly, pluripotency-related genes were highly expressed at the end of all passages. These results demonstrate the successful adaptation of the expansion strategy developed for the ambr15 system to the UniVessel system.

[0109] In this experiment, we successfully adapted our iPSC expansion strategy to the UniVessel system, which allows for scale-up without further modification. High-quality iPSCs were successfully passaged three times and cultured for 18 days in the UniVessel system, which has a larger volume than the ambr15 system.

[0110] Similar results were obtained in a 2 L culture system, further demonstrating that the propagation method of the present invention is highly suitable for scale-up and large-scale production of PSCs.

[0111] References Burridge, PW, Holmstrom, A., and Wu, JC (2015). Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. Curr. Protoc. Hum. Genet. 87, 21.3.1. Chen, VC, Ye, J., Shukla, P., Hua, G., Chen, D., Lin, Z., Liu, J., Chai, J., Gold, J., Wu, J., et al. (2015). Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. Stem Cell Res. 15, 365-375. Kropp et al. “Progress and challenges in large-scale expansion of human pluripotent stem cells” Process Biochemistry, Vol. 59, Part B, August 2017, Pages 244-254.

Claims

1. 1. A method for expanding pluripotent stem cells (PSCs) in suspension culture in a bioreactor, comprising the steps of: (i) adding an inhibitor of ROCK (ROCKi) to aggregates of pluripotent stem cells cultured in suspension in a bioreactor, wherein the ROCKi is added 2 to 4 hours before step (ii); (ii) adding a cell dissociation agent, thereby dissociating the pluripotent stem cell aggregates, wherein the cell dissociation agent is a chelating agent; (iii) diluting the cell dissociation agent added in step (ii) by adding an excess volume of culture medium sufficient to reduce the concentration of the cell dissociation agent to a concentration at which cell aggregates can reform; and (iv) culturing the mixture obtained in step (iii) under suitable conditions that allow proliferation of PSCs. wherein steps (i) to (iv) are carried out in the same bioreactor.

2. 2. The method of claim 1, wherein the chelating agent is selected from the group consisting of ethylenediaminetetraacetate (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), iminodisuccinic acid (IDS), polyaspartic acid, ethylenediamine-N,N'-disuccinic acid (EDDS), citrate, citric acid, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), methylglycine diacetic acid (MGDA), and combinations thereof.

3. 3. The method of claim 2, wherein the cell dissociation agent is EDTA.

4. 4. The method of claim 3, wherein the final concentration of EDTA in step (ii) is at least 100 μM EDTA, in the range of 100 to 1000 μM EDTA, in the range of 250 to 750 μM EDTA, in the range of 400 to 600 μM EDTA, or 500 μM EDTA.

5. 5. The method of claim 3 or 4, wherein the final concentration of EDTA in step (ii) is 500 μM EDTA.

6. 6. The method of any one of claims 3 to 5, wherein the concentration of EDTA in step (iii) after adding the excess volume of culture medium is 100 μM or less, 95 μM or less, 90 μM or less, 80 μM or less, 70 μM or less, in the range of 100 to 1 μM EDTA, or in the range of 90 to 1 μM EDTA.

7. 7. The method of any one of claims 1 to 6, wherein the excess volume is at least 5 times greater than the volume of the cell dissociation agent.

8. The method of any one of claims 1 to 7, wherein the excess volume of culture medium in step (iii) comprises ROCKi.

9. The method of any one of claims 1 to 8, further comprising the steps of: (v) replacing the medium with medium essentially free of ROCKi.

10. 10. The method of any one of claims 1 to 9, wherein step (iv) is carried out for 1 to 3 days.

11. 11. The method of any one of claims 1 to 10, wherein step (iv) is carried out for two days.

12. 10. The method of claim 9, wherein step (v) begins 1 to 3 days after step (iii).

13. 13. The method of claim 9 or 12, wherein step (v) begins two days after step (iii).

14. 14. The method of any one of claims 1 to 13, wherein the ROCKi is selected from the group consisting of AS1892802, fasudil hydrochloride, GSK 269962, GSK 429286, H 1152, HA 1100, OXA 06, RKI 1447, SB 772077B, SR 3677, TC-S 7001, thiazovivin, Y27632, and combinations thereof.

15. The method of any one of claims 1 to 14, wherein the ROCKi is Y27632.

16. 16. The method of claim 15, wherein Y27632 is added to a final concentration of 10 μM.

17. The addition of an excess volume of culture medium in step (iii) increases the number of cells in the culture medium to 1×10 5 ~1×10 6 cells / ml, 1.5×10 5 ~7.5×10 5 cells / ml, 2×10 5 ~5×10 5 cells / ml, 2×10 5 ~3×10 5 cells / ml, or 2.5 × 10 5 17. The method of any one of claims 1 to 16, wherein the method results in cells / ml.

18. 18. The method of any one of claims 1 to 17, wherein the culture medium is selected from the group consisting of IPS-Brew, E8, StemFlex, mTeSR1, and PluriSTEM.

19. 20. The method of claim 18, wherein the culture medium is iPS-Brew.

20. 20. The method of any one of claims 1 to 19, wherein the culture media of steps (i) and (iii) are essentially identical.

21. 21. The method of any one of claims 1 to 20, wherein the temperature of the culture medium is 30 to 50°C, 35 to 40°C, 36 to 38°C, or 37°C.

22. 22. The method of any one of claims 1 to 21, wherein the temperature of the culture medium is 37°C.

23. 23. The method of any one of claims 1-22, wherein steps (i)-(iv) or (i)-(v) are repeated 1, 2, 3, 4, 5, at least 5, or at least 10 times.

24. 24. The method of any one of claims 1 to 23, wherein the pluripotent stem cells are selected from the group consisting of induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), parthenogenetic stem cells (pPSCs), and nuclear transfer-derived PSCs (ntPSCs).

25. 24. The method of claim 23, wherein the PSCs maintain pluripotency after each repetition of steps (i) to (iv) or (i) to (v).

26. The method of any one of claims 1 to 25, wherein the pluripotent stem cells are TC-1133 cells.

27. 27. The method of any one of claims 1 to 26, wherein the aggregates of step (ii) have an average diameter of between 180 μm and 250 μm.

28. 28. The method of any one of claims 1 to 27, wherein the aggregates of step (ii) have an average diameter of between 200 μm and 250 μm.

29. 29. The method of any one of claims 1 to 28, wherein the aggregates of step (ii) have an average diameter of 200 μm.

30. 30. The method of any one of claims 1 to 29, wherein the aggregates are dissociated in step (ii) for at least 1 minute, at least 2 minutes, at least 3 minutes, at least 5 minutes, at least 10 minutes, 1 to 20 minutes, 10 to 20 minutes, 10 to 15 minutes, or up to 15 minutes.

31. 31. The method of any one of claims 1 to 30, wherein the aggregates are dissociated in step (ii) for 15 minutes.

32. 32. An aggregate of PSCs in suspension culture obtained using the method of any one of claims 1 to 31.

Images